<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37511014</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>14</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>No Association of Multiple Sclerosis with <i>C9orf72</i> Hexanucleotide Repeat Size in an Austrian Cohort.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11254</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241411254</ELocationID><Abstract><AbstractText>Multiple Sclerosis (MS) is a common immune-mediated disorder of the central nervous system that affects young adults and is characterized by demyelination and neurodegeneration. Recent studies have associated <i>C9orf72</i> intermediate repeat expansions with MS. The objective of this study was to investigate whether <i>C9orf72</i> repeat length is associated with MS or with a specific disease course in a monocentric Austrian MS cohort. Genotyping of 382 MS patients and 643 non-neurological controls for <i>C9orf72</i> repeat expansions was performed. The study did not find a difference in the distribution of repeat numbers between controls and MS cases (median repeat units = 2; <i>p</i> = 0.39). Additionally, sub-analysis did not establish a link between intermediate repeats and MS (<i>p</i> = 0.23) and none of the patients with progressive disease course carried an intermediate allele (20-30 repeat units). Exploratory analysis for different cut-offs (of &#x2265;7, &#x2265;17, and &#x2265;24) did not reveal any significant differences in allele frequencies between MS and controls. However, the study did identify a progressive MS patient with a pathogenic <i>C9orf72</i> expansion and probable co-existing behavioral variant frontotemporal dementia (bvFTD) in a retrospective chart review. In conclusion, this study did not find evidence supporting an association between <i>C9orf72</i> repeat length and MS or a specific disease course in the Austrian MS cohort. However, the identification of a progressive MS patient with a pathogenic <i>C9orf72</i> expansion and probable co-existing with FTD highlights the complexity and challenges involved in recognizing distinct neurodegenerative diseases that may co-occur in MS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7904-8482</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leutmezer</LastName><ForeName>Fritz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimprich</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1668-5177</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmied</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf6;gmann</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4688-8482</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zrzavy</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8909-1591</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020528" MajorTopicYN="N">Multiple Sclerosis, Chronic Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72 repeat expansion</Keyword><Keyword MajorTopicYN="N">disease heterogeneity</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia (FTD)</Keyword><Keyword MajorTopicYN="N">genetic variants</Keyword><Keyword MajorTopicYN="N">intermediate repeat length</Keyword><Keyword MajorTopicYN="N">multiple sclerosis (MS)</Keyword></KeywordList><CoiStatement>T.K., F.L., A.Z., C.S. and T.Z. have nothing to disclose. T.B. has received honoraria and consulting fees from Almirall, Bayer, Biogen, Biologix, Bionorica, Celgene/BMS, Genesis, GSK, Horizon, Janssen-Cilag, Jazz, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, TEVA, TG Therapeutics, and UCB. His institution has received financial support by unrestricted research grants from Almirall, Biogen, Bayer, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and TEVA, and honoraria for participation in clinical trials sponsored by Alexion, Bayer, Biogen, Celgene/BMS, Merck, Novartis, Octapharma, Roche, Sanofi, and TEVA. In the past 36 months, E.S. received grants from Roche, Eisai, FFG/AAL, Horizon2020 and the Austrian Alzheimer Association (all to the institution). E.S. received consulting fees from Biogen and received support for attending meetings and/or travel from Roche. E.S. received for lectures, presentations, speakers bureaus, manuscript writing, or educational events payment by Biogen, Roche, Eisai, and Novartis. E. St&#xf6;gmann participated on an advisory board (Biogen, Roche, Eisai) and held leadership or a fiduciary role in scientific societies (Austrian Alzheimer Association, the EAN scientific panel dementia). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37511014</ArticleId><ArticleId IdType="pmc">PMC10378763</ArticleId><ArticleId IdType="doi">10.3390/ijms241411254</ArticleId><ArticleId IdType="pii">ijms241411254</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Attfield K.E., Jensen L.T., Kaufmann M., Friese M.A., Fugger L. The immunology of multiple sclerosis. Nat. Rev. Immunol. 2022;22:734&#x2013;750. doi: 10.1038/s41577-022-00718-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00718-z</ArticleId><ArticleId IdType="pubmed">35508809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or A., Li R. Cellular immunology of relapsing multiple sclerosis: Interactions, checks, and balances. Lancet Neurol. 2021;20:470&#x2013;483. doi: 10.1016/S1474-4422(21)00063-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00063-6</ArticleId><ArticleId IdType="pubmed">33930317</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2019;t Hart B.A., Luchicchi A., Schenk G.J., Stys P.K., Geurts J.J.G. Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis. Ann. Clin. Transl. Neurol. 2021;8:1709&#x2013;1719. doi: 10.1002/acn3.51401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51401</ArticleId><ArticleId IdType="pmc">PMC8351380</ArticleId><ArticleId IdType="pubmed">34156169</ArticleId></ArticleIdList></Reference><Reference><Citation>Stys P.K., Zamponi G.W., van Minnen J., Geurts J.J. Will the real multiple sclerosis please stand up? Nat. Rev. Neurosci. 2012;13:507&#x2013;514. doi: 10.1038/nrn3275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3275</ArticleId><ArticleId IdType="pubmed">22714021</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende E.L., Jackson J.L., White A., Seelaar H., van Blitterswijk M., Van Swieten J.C. Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions. J. Neurol. Neurosurg. Psychiatry. 2021;92:502&#x2013;509. doi: 10.1136/jnnp-2020-325377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325377</ArticleId><ArticleId IdType="pmc">PMC8053328</ArticleId><ArticleId IdType="pubmed">33452054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail A., Cooper-Knock J., Highley J.R., Milano A., Kirby J., Goodall E., Lowe J., Scott I., Constantinescu C.S., Walters S.J., et al. Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72. J. Neurol. Neurosurg. Psychiatry. 2013;84:79&#x2013;87. doi: 10.1136/jnnp-2012-303326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303326</ArticleId><ArticleId IdType="pubmed">23085936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorefice L., Murru M.R., Fenu G., Corongiu D., Frau J., Cuccu S., Coghe G.C., Tranquilli S., Cocco E., Marrosu M.G. A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. J. Neurol. Sci. 2015;357:229&#x2013;234. doi: 10.1016/j.jns.2015.07.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.07.036</ArticleId><ArticleId IdType="pubmed">26233805</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenoglio C., De Riz M., Villa C., Serpente M., Ridolfi E., Bonsi R., Cioffi S.M., Barone C., Pietroboni A., Calvi A., et al. C9ORF72 repeat expansion not detected in patients with multiple sclerosis. Neurobiol. Aging. 2014;35:1213.e1&#x2013;1213.e2. doi: 10.1016/j.neurobiolaging.2013.10.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.10.096</ArticleId><ArticleId IdType="pubmed">24355526</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira Santos M., Caldeira I., Gromicho M., Pronto-Laborinho A., de Carvalho M. Brain white matter demyelinating lesions and amyotrophic lateral sclerosis in a patient with C9orf72 hexanucleotide repeat expansion. Mult. Scler. Relat. Disord. 2017;17:1&#x2013;4. doi: 10.1016/j.msard.2017.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2017.06.010</ArticleId><ArticleId IdType="pubmed">29055436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiloca C., Sorosina M., Esposito F., Peroni S., Colombrita C., Ticozzi N., Ratti A., Martinelli-Boneschi F., Silani V. No C9orf72 repeat expansion in patients with primary progressive multiple sclerosis. Mult. Scler. Relat. Disord. 2018;25:192&#x2013;195. doi: 10.1016/j.msard.2018.07.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2018.07.047</ArticleId><ArticleId IdType="pubmed">30099204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng A.S.L., Tan E.K. Intermediate C9orf72 alleles in neurological disorders: Does size really matter? J. Med. Genet. 2017;54:591&#x2013;597. doi: 10.1136/jmedgenet-2017-104752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2017-104752</ArticleId><ArticleId IdType="pmc">PMC5574395</ArticleId><ArticleId IdType="pubmed">28689190</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpente M., Fenoglio C., Arighi A., Fumagalli G.G., Arcaro M., Sorrentino F., Visconte C., Scarpini E., Galimberti D. Analysis of C9orf72 Intermediate Alleles in a Retrospective Cohort of Neurological Patients: Risk Factors for Alzheimer&#x2019;s Disease? J. Alzheimer&#x2019;s Dis. JAD. 2021;81:1445&#x2013;1451. doi: 10.3233/JAD-210249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-210249</ArticleId><ArticleId IdType="pubmed">33935096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaivola K., Kiviharju A., Jansson L., Rantalainen V., Eriksson J.G., Strandberg T.E., Laaksovirta H., Renton A.E., Traynor B.J., Myllykangas L., et al. C9orf72 hexanucleotide repeat length in older population: Normal variation and effects on cognition. Neurobiol. Aging. 2019;84:242.e7&#x2013;242.e12. doi: 10.1016/j.neurobiolaging.2019.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.026</ArticleId><ArticleId IdType="pmc">PMC8981799</ArticleId><ArticleId IdType="pubmed">30979436</ArticleId></ArticleIdList></Reference><Reference><Citation>Konig T., Wurm R., Parvizi T., Silvaieh S., Hotzy C., Cetin H., Klotz S., Gelpi E., Bancher C., Benke T., et al. C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. Neurobiol. Dis. 2022;175:105927. doi: 10.1016/j.nbd.2022.105927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105927</ArticleId><ArticleId IdType="pubmed">36379394</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Tortosa E., Gallego J., Guerrero-Lopez R., Marcos A., Gil-Neciga E., Sainz M.J., Diaz A., Franco-Macias E., Trujillo-Tiebas M.J., Ayuso C., et al. C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration. Neurology. 2013;80:366&#x2013;370. doi: 10.1212/WNL.0b013e31827f08ea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f08ea</ArticleId><ArticleId IdType="pubmed">23284068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K., Bademci G., Kohli M.M., Beecham G.W., Wang L., Young J.I., Nahab F., Martin E.R., Gilbert J.R., Benatar M., et al. C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease. Ann. Hum. Genet. 2013;77:351&#x2013;363. doi: 10.1111/ahg.12033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ahg.12033</ArticleId><ArticleId IdType="pmc">PMC3815478</ArticleId><ArticleId IdType="pubmed">23845100</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J., Gijselinck I., Dillen L., Van Langenhove T., Theuns J., Engelborghs S., Philtjens S., Vandenbulcke M., Sleegers K., Sieben A., et al. A pan-European study of the C9orf72 repeat associated with FTLD: Geographic prevalence, genomic instability, and intermediate repeats. Hum. Mutat. 2013;34:363&#x2013;373. doi: 10.1002/humu.22244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22244</ArticleId><ArticleId IdType="pmc">PMC3638346</ArticleId><ArticleId IdType="pubmed">23111906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Mossevelde S., van der Zee J., Sieben A., Engelborghs S., De Bleecker J., Ivanoiu A., Deryck O., Edbauer D., Zhang M., et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol. Psychiatry. 2016;21:1112&#x2013;1124. doi: 10.1038/mp.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.159</ArticleId><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali C.P., Patino M., Tai Y.K., Ho W.Y., McLean C.A., Morris C.M., Seeley W.W., Miller B.L., Gaig C., Vonsattel J.P.G., et al. C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathol. 2019;138:795&#x2013;811. doi: 10.1007/s00401-019-02045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02045-5</ArticleId><ArticleId IdType="pmc">PMC6802287</ArticleId><ArticleId IdType="pubmed">31327044</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A., Al Khleifat A., Jones A.R., Sproviero W., Shatunov A., Opie-Martin S., Alzheimer&#x2019;s Disease Neuroimaging I., Morrison K.E., Shaw P.J., Shaw C.E., et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol. Commun. 2019;7:115. doi: 10.1186/s40478-019-0724-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0724-4</ArticleId><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Biasiotto G., Zanella I. The effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseases. Mult. Scler. Relat. Disord. 2019;27:42&#x2013;43. doi: 10.1016/j.msard.2018.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2018.10.004</ArticleId><ArticleId IdType="pubmed">30312838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiloca C., Sorosina M., Esposito F., Peroni S., Colombrita C., Ticozzi N., Ratti A., Martinelli-Boneschi F., Silani V. Response to the commentary &#x201c;The effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseases&#x201d; by Biasiotto G and Zanella I. Mult. Scler. Relat. Disord. 2019;27:79&#x2013;80. doi: 10.1016/j.msard.2018.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2018.10.007</ArticleId><ArticleId IdType="pubmed">30347338</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Pt 9Brain. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden J.S., Rollinson S., Thompson J.C., Harris J.M., Stopford C.L., Richardson A.M., Jones M., Gerhard A., Davidson Y.S., Robinson A., et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Pt 3Brain. 2012;135:693&#x2013;708. doi: 10.1093/brain/awr355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr355</ArticleId><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Solje E., Aaltokallio H., Koivumaa-Honkanen H., Suhonen N.M., Moilanen V., Kiviharju A., Traynor B., Tienari P.J., Hartikainen P., Remes A.M. The Phenotype of the C9ORF72 Expansion Carriers According to Revised Criteria for bvFTD. PLoS ONE. 2015;10:e0131817. doi: 10.1371/journal.pone.0131817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0131817</ArticleId><ArticleId IdType="pmc">PMC4493025</ArticleId><ArticleId IdType="pubmed">26146826</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek K.F., van Blitterswijk M., Baker M.C., Petrucelli L., Rademakers R., Dickson D.W. Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia. JAMA Neurol. 2014;71:775&#x2013;781. doi: 10.1001/jamaneurol.2013.6368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6368</ArticleId><ArticleId IdType="pmc">PMC4197801</ArticleId><ArticleId IdType="pubmed">24756204</ArticleId></ArticleIdList></Reference><Reference><Citation>Block N.R., Sha S.J., Karydas A.M., Fong J.C., De May M.G., Miller B.L., Rosen H.J. Frontotemporal Dementia and Psychiatric Illness: Emerging Clinical and Biological Links in Gene Carriers. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry. 2016;24:107&#x2013;116. doi: 10.1016/j.jagp.2015.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2015.04.007</ArticleId><ArticleId IdType="pmc">PMC4686378</ArticleId><ArticleId IdType="pubmed">26324540</ArticleId></ArticleIdList></Reference><Reference><Citation>Saracino D., Geraudie A., Remes A.M., Ferrieux S., Nogues-Lassiaille M., Bottani S., Cipriano L., Houot M., Funkiewiez A., Camuzat A., et al. Primary progressive aphasias associated with C9orf72 expansions: Another side of the story. Cortex. 2021;145:145&#x2013;159. doi: 10.1016/j.cortex.2021.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2021.09.005</ArticleId><ArticleId IdType="pubmed">34717271</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli V., Rodegher M., Moiola L., Comi G. Late onset multiple sclerosis: Clinical characteristics, prognostic factors and differential diagnosis. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2004;25((Suppl. 4)):S350&#x2013;S355. doi: 10.1007/s10072-004-0339-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-004-0339-8</ArticleId><ArticleId IdType="pubmed">15727232</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodin D.S. Disease-modifying therapy in multiple sclerosis: Update and clinical implications. Neurology. 2008;71((Suppl. 3)):S8&#x2013;S13. doi: 10.1212/WNL.0b013e31818f3d8b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31818f3d8b</ArticleId><ArticleId IdType="pubmed">19064873</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco M., Ruano L., Portaccio E., Goretti B., Niccolai C., Patti F., Chisari C., Gallo P., Grossi P., Ghezzi A., et al. Aging with multiple sclerosis: Prevalence and profile of cognitive impairment. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2019;40:1651&#x2013;1657. doi: 10.1007/s10072-019-03875-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03875-7</ArticleId><ArticleId IdType="pubmed">31011932</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese P., Penner I.K. Cognitive dysfunctions in multiple sclerosis&#x2014;A &#x201c;multiple disconnection syndrome&#x201d;? J. Neurol. 2007;254((Suppl. 2)):II18&#x2013;II21. doi: 10.1007/s00415-007-2006-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-007-2006-5</ArticleId><ArticleId IdType="pubmed">17503122</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiaravalloti N.D., DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7:1139&#x2013;1151. doi: 10.1016/S1474-4422(08)70259-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70259-X</ArticleId><ArticleId IdType="pubmed">19007738</ArticleId></ArticleIdList></Reference><Reference><Citation>Londono D.P., Arumaithurai K., Constantopoulos E., Basso M.R., Reichard R.R., Flanagan E.P., Keegan B.M. Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis. Brain Commun. 2022;4:fcac167. doi: 10.1093/braincomms/fcac167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac167</ArticleId><ArticleId IdType="pmc">PMC9272064</ArticleId><ArticleId IdType="pubmed">35822102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G.G., Alafuzoff I., Al-Sarraj S., Arzberger T., Bogdanovic N., Capellari S., Ferrer I., Gelpi E., Kovari V., Kretzschmar H., et al. Mixed brain pathologies in dementia: The BrainNet Europe consortium experience. Dement. Geriatr. Cogn. Disord. 2008;26:343&#x2013;350. doi: 10.1159/000161560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000161560</ArticleId><ArticleId IdType="pubmed">18849605</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi J., Kovacs G.G. Prevalence of mixed pathologies in the aging brain. Alzheimer&#x2019;s Res. Ther. 2014;6:82. doi: 10.1186/s13195-014-0082-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0082-1</ArticleId><ArticleId IdType="pmc">PMC4239398</ArticleId><ArticleId IdType="pubmed">25419243</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162&#x2013;173. doi: 10.1016/S1474-4422(17)30470-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30470-2</ArticleId><ArticleId IdType="pubmed">29275977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sorensen P.S., Thompson A.J., Wolinsky J.S., Balcer L.J., Banwell B., Barkhof F., et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83:278&#x2013;286. doi: 10.1212/WNL.0000000000000560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000560</ArticleId><ArticleId IdType="pmc">PMC4117366</ArticleId><ArticleId IdType="pubmed">24871874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>